Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure
Cell Stem Cell · 2024-04 · 31 (4) · 484-498.e5
DOI: 10.1016/j.stem.2024.02.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Stem Cell, 2024-04. Verfasst von Xiang Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chine…. Hauptthemen laut MEDLINE: Liver Failure, Acute, Liver Failure. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Alginate-encapsulated hepatocyte transplantation is a promising strategy to treat liver failure. However, its clinical application was impeded by the lack of primary human hepatocytes and difficulty in controlling their quality. We previously reported proliferating human hepatocytes (ProliHHs). Here, quality-controlled ProliHHs were produced in mass and engineered as liver organoids to improve their maturity. Encapsulated ProliHHs liver organoids (eLO) were intraperitoneally transplanted to treat liver failure animals. Notably, eLO treatment increased the survival of mice with post-hepatectomy liver failure (PHLF) and ameliorated hyperammonemia and hypoglycemia by providing liver functions. Additionally, eLO treatment protected the gut from PHLF-augmented permeability and normalized the increased serum endotoxin and inflammatory response, which facilitated liver regeneration. The therapeutic effect of eLO was additionally proved in acetaminophen-induced liver failure. Furthermore, we performed assessments of toxicity and biodistribution, demonstrating that eLO had no adverse effects on animals and remained non-tumorigenic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Cell Biology, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Sha…
- CAS Key Laboratory of Computational Biology, Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
- Department of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
- Paediatric Liver GI and Nutrition Center, King's College Hospital, London, UK; Dhawan Lab at the Mowat Labs, Institute of Liver Studies, King's College London at King's College Hospital, London, UK.
Zitieren
APA
Yuan, X., Wu, J., Sun, Z., Cen, J., Shu, Y., Wang, C., Li, H., Lin, D., Zhang, K., Wu, B., Dhawan, A., Zhang, L., & Hui, L. (2024). Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure. Cell Stem Cell, 31(4), 484-498.e5. https://doi.org/10.1016/j.stem.2024.02.005
Vancouver
Yuan X, Wu J, Sun Z, Cen J, Shu Y, Wang C, et al. Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure. Cell Stem Cell. 2024;31(4):484-498.e5. doi:10.1016/j.stem.2024.02.005
BibTeX
@article{Yuan2024,
author = {Yuan, Xiang and Wu, Jingqi and Sun, Zhen and Cen, Jin and Shu, Yajing and Wang, Chenhua and Li, Hong and Lin, Dongni and Zhang, Kun and Wu, Baihua and Dhawan, Anil and Zhang, Ludi and Hui, Lijian},
title = {Preclinical efficacy and safety of encapsulated proliferating human hepatocyte organoids in treating liver failure},
journal = {Cell Stem Cell},
year = {2024},
volume = {31},
number = {4},
pages = {484--498.e5},
doi = {10.1016/j.stem.2024.02.005}
}
EUVIMED